Simon et al. used RRM1 and ERCC1 as molecular determinants, and found that RRM1- and ERCC1-tailored selection of first-line therapy could improve response, overall survival (OS), and PFS over standard treatments in patients with NSCLC [23]. Here, RRM1 is linked to non-small cell lung carcinoma.